Arrhythmia refers to any change from the normal sequence of electrical impulses, causing abnormal heart rhythms. A fast heart rate (in adults, more than 100 beats per minute) is known as tachycardia. A slow heart rate (less than 60 beats per minute) is known as bradycardia. When the heart does not beat properly, it cannot pump blood effectively. When the heart does not pump blood effectively, the lungs, brain and all other organs cannot work properly and may shut down or be damaged. Some arrhythmias are so brief that the overall heart rate or rhythm is not greatly affected. But if arrhythmias last longer, they may cause the heart rate to be too slow or too fast or the heart rhythm to be erratic, so the heart pumps less effectively. The signs and symptoms of arrhythmia include anxiety, weakness, dizziness, and light-headedness, fainting or nearly fainting, sweating, shortness of breath and chest pain. The treatment of arrhythmia includes anti-arrhythmic and anticoagulants. Some of the drug candidates in the pipeline for treating arrhythmias include, but are not limited to HBI-3000, Eleclazine and Aladorian. Some of the companies with their drug candidates in the arrhythmias pipeline include Allosteros Therapeutics Inc., Cynata Therapeutics Limited, Gilead Sciences Inc., and Ono Pharmaceutical Co. Ltd.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.